Business Context and Reporting Period
This Form 8-K filing by Seres Therapeutics, Inc. reports a corporate governance event dated July 7, 2017. The company, incorporated in Delaware, is an emerging growth company.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Director Retainer: $35,000
- Audit Committee Retainer: $7,500
- Stock Option Grant: 30,000 shares with an exercise price of $11.14 per share.
Material Changes
The Board of Directors increased its size from seven to eight members. Willard H. Dere, M.D., was elected as a Class I director and appointed to the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document focuses solely on the appointment and compensatory arrangements for the new director.
Key Facts for Investor Verification
- Willard H. Dere, M.D., joined the Board and Audit Committee on July 7, 2017.
- Dr. Dere received an initial stock option award of 30,000 shares vesting over four years.
- The exercise price of the options was set at $11.14, the closing stock price on the grant date.
- No financial results or operational updates are included in this specific report.